发明名称 |
Multi-indication mRNA cancer immunotherapy |
摘要 |
Synthetic bacterial messenger RNA can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mRNA obtained from DNA that encodes an immunogenic bacterial protein. An immune response to the cancer is generated from direct administration of the mRNA in vivo or administration of vaccines prepared from cancer cells in vitro. |
申请公布号 |
US9636388(B2) |
申请公布日期 |
2017.05.02 |
申请号 |
US201615114943 |
申请日期 |
2016.05.19 |
申请人 |
MORPHOGENESIS, INC. |
发明人 |
Lawman Michael J. P.;Lawman Patricia D.;Gentilini Meghan;Ramiya Vijay;Bastawrous Marina Victor Abdelmaseeh |
分类号 |
A61K31/70;A61K48/00;C07H21/04;A61K39/00;A61K45/06;A01K67/00 |
主分类号 |
A61K31/70 |
代理机构 |
Saliwanchik, Lloyd & Eisenschenk |
代理人 |
Saliwanchik, Lloyd & Eisenschenk |
主权项 |
1. A method of treating a cancer patient, comprising administering a ribonucleic acid having the sequence of SEQ ID NO: 1 directly into a tumor or tumor draining lymph node of a cancer patient. |
地址 |
Tampa FL US |